Jazz Pharmaceuticals plc (F:J7Z) — Market Cap & Net Worth
Market Cap & Net Worth: Jazz Pharmaceuticals plc (J7Z)
Jazz Pharmaceuticals plc (F:J7Z) has a market capitalization of $8.86 Billion (€7.58 Billion) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #2434 globally and #497 in its home market, demonstrating a -0.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jazz Pharmaceuticals plc's stock price €172.35 by its total outstanding shares 60765116 (60.77 Million). Analyse Jazz Pharmaceuticals plc cash conversion from operations to see how efficiently the company converts income to cash.
Jazz Pharmaceuticals plc Market Cap History: 2015 to 2026
Jazz Pharmaceuticals plc's market capitalization history from 2015 to 2026. Data shows growth from $9.24 Billion to $12.24 Billion (3.42% CAGR).
Jazz Pharmaceuticals plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jazz Pharmaceuticals plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.03x
Jazz Pharmaceuticals plc's market cap is 2.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.78x
Jazz Pharmaceuticals plc's market cap is 14.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $9.24 Billion | $1.32 Billion | $329.54 Million | 6.98x | 28.04x |
| 2016 | $7.25 Billion | $1.49 Billion | $396.83 Million | 4.87x | 18.27x |
| 2017 | $8.02 Billion | $1.62 Billion | $487.85 Million | 4.96x | 16.44x |
| 2018 | $7.60 Billion | $1.89 Billion | $447.10 Million | 4.02x | 17.00x |
| 2019 | $9.45 Billion | $2.16 Billion | $523.37 Million | 4.37x | 18.05x |
| 2020 | $9.24 Billion | $2.36 Billion | $238.62 Million | 3.91x | 38.70x |
| 2021 | $8.25 Billion | $3.09 Billion | -$329.67 Million | 2.67x | N/A |
| 2022 | $10.48 Billion | $3.66 Billion | -$224.06 Million | 2.86x | N/A |
| 2023 | $7.87 Billion | $3.83 Billion | $414.83 Million | 2.05x | 18.98x |
| 2024 | $8.28 Billion | $4.07 Billion | $560.12 Million | 2.03x | 14.78x |
Competitor Companies of J7Z by Market Capitalization
Companies near Jazz Pharmaceuticals plc in the global market cap rankings as of May 2, 2026.
Key companies related to Jazz Pharmaceuticals plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Jazz Pharmaceuticals plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Jazz Pharmaceuticals plc's market cap moved from $9.24 Billion to $ 12.24 Billion, with a yearly change of 3.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.24 Billion | +20.69% |
| 2025 | €10.14 Billion | +22.52% |
| 2024 | €8.28 Billion | +5.14% |
| 2023 | €7.87 Billion | -24.85% |
| 2022 | €10.48 Billion | +26.99% |
| 2021 | €8.25 Billion | -10.65% |
| 2020 | €9.24 Billion | -2.26% |
| 2019 | €9.45 Billion | +24.30% |
| 2018 | €7.60 Billion | -5.25% |
| 2017 | €8.02 Billion | +10.66% |
| 2016 | €7.25 Billion | -21.55% |
| 2015 | €9.24 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Jazz Pharmaceuticals plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.86 Billion USD |
| MoneyControl | $8.86 Billion USD |
| MarketWatch | $8.86 Billion USD |
| marketcap.company | $8.86 Billion USD |
| Reuters | $8.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LG… Read more